Martin Holst Lange 0.5 5 ideas

"In the study that read out today, we saw 23% weight loss with Cagresema... The 25%, which we saw with the comparator drug, is actually the best data that has been seen so far... it stands alone." The CSO explicitly admits that their new combination therapy (CagriSema) underperformed the comparator (Lilly's asset) in pure weight loss efficacy (23% vs 25%). In the obesity duopoly, the market pays a premium for "best-in-class" efficacy. This data point reinforces Lilly's dominance and suggests Novo failed to leapfrog them in this cycle. Long LLY as the undisputed efficacy leader in the GLP-1 space. Future Novo studies (REDEFINE 11) successfully optimizing dosing to beat Lilly's numbers.

"We need to have what we call a bespoke titration algorithms to really allow patients to titrate the very powerful treatment... In this setting, we could not manage to implement the those learnings... The jury is still out of what can CACRESMA actually achieve." Management is asking investors to look past the current disappointment (23% loss) and wait for the "REDEFINE 11" study, where they have adjusted the dosing speed (titration). Until that data reads out, the stock lacks a near-term catalyst to reclaim the "efficacy crown" from Lilly. The thesis shifts from "proven winner" to "show me story." Watch/Neutral. Avoid aggressive longs until REDEFINE 11 data validates the titration hypothesis. REDEFINE 11 confirms that 23-24% is the ceiling, permanently cementing Novo as #2 in efficacy.

"To an extent, in our current portfolio, we have all of that [efficacy, safety, comorbidities]... We also have the best in class oral already on the market... and the senagemtide offering that is starting phase three." When asked about M&A to bolster the pipeline, the CSO pivoted to praising their internal assets (Amycretin, Tri-agonists). This signals a reluctance to pay high premiums for external biotech assets in the near term, dampening M&A speculation for smaller obesity players hoping for a Novo buyout. Avoid buying speculative small-cap obesity biotechs solely on the premise of a near-term Novo acquisition. Novo panics due to continued stock underperformance and executes a "buy vs. build" pivot.